Search PubMed⌕ Search

Biomedical subjects

B LeBlanc

Publications and source records attributed to B LeBlanc.

At least 37 records · Page 2Linked to original sources
PubMed1989

In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.

The in-vitro activity of PD 117558, a new quinolone antimicrobial agent, was compared to that of four other quinolones, imipenem and ceftazidime against a variety of Gram-positive and Gram-negative isolates from cancer patients. PD 117558 was found to have a broad antimicrobial spectrum with excellent activity against all Gram-positive isolates (including methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus faecalis and Group JK-corynebacteria). It was also extremely active against Gram-negative bacilli with the exception of Pseudomonas aeruginosa against which ciprofloxacin was more active. Fleroxacin was slightly less active and S-25930 and S-25932 considerably less active than PD 117558. PD 117558 also had lower minimal inhibitory concentrations for most organisms tested than either imipenem or ceftazidime.

4-Quinolones↗
PubMed1988

Comparative in vitro activity of the two new 4-quinolones S-25930 and S-25932 against gram-positive bacteria isolated from cancer patients.

The in vitro activity of S-25930 and S-25932, two new quinolone antimicrobial agents, against 306 gram-positive organisms representing 12 bacterial species, was evaluated and compared with the activity of ciprofloxacin, difloxacin, enoxacin, amifloxacin and A-56620. Both agents were active against staphylococcal species (including methicillin-resistant and coagulase-negative isolates), Bacillus spp. and group JK diphtheroids. They were less active against streptococcal species and Listeria monocytogenes. Their activity against most isolates was superior to that of amifloxacin, enoxacin and difloxacin and similar to that of ciprofloxacin and A-56620.

Anti-Bacterial Agents↗
PubMed1988

Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.

The in vitro activity of temafloxacin, a new difluoro quinolone agent, against 725 bacterial isolates representing 32 species was evaluated in comparison with that of ciprofloxacin. Temafloxacin inhibited the majority of Enterobacteriaceae isolates at a concentration of less than or equal to 0.5 microgram/ml. It was also extremely active against Acinetobacter spp. and Aeromonas hydrophila. Its activity was 2-8 fold less than that of ciprofloxacin against most gram-negative isolates. Methicillin-susceptible and methicillin-resistant Staphylococcus aureus, coagulase-negative Staphylococcus spp., Streptococcus spp., Listeria monocytogenes, Bacillus spp. and group JK corynebacteria were inhibited at concentrations equal to that of ciprofloxacin.

Anti-Infective Agents↗
PubMed1988

In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.

The in vitro activity of Fleroxacin (Ro23-6240; AM 833), a new fluorinated 4-quinolone, was compared to that of ciprofloxacin, enoxacin and A-56620, against 747 isolates from cancer patients. Fleroxacin inhibited more than 90% of Enterobacteriacea isolates at a concentration of less than or equal to 0.25 micrograms/ml. It was also extremely active against Aeromonas hydrophila and Haemophilus influenzae isolates with MIC90 values of 0.12 and 0.06 micrograms/ml, respectively. The MIC90 for Acinetobacter spp. was 1.0 micrograms/ml, for Pseudomonas aeruginosa and Pseudomonas fluorescens 4.0 micrograms/ml, and for other Pseudomonas spp., 8.0 micrograms/ml. Staphylococcus aureus isolates including methicillin-resistant strains were inhibited by less than or equal to 1.0 microgram/ml. The MIC90 for three different species of coagulase-negative Staphylococci was 1.0 microgram/ml. Streptococcal species required 8-16 micrograms/ml for inhibition. Fleroxacin was also active against group JK-diphtheroids and Bacillus cereus. The overall activity of fleroxacin was similar to that of enoxacin and less than that of A-56620 and ciprofloxacin.

Anti-Infective Agents↗
PubMed1987

In-vitro activity of LY146032 against gram-positive isolates from cancer patients.

The in-vitro activity of LY146032 was compared with that of other antibiotics against Gram-positive organisms, mostly isolated from cancer patients. LY146032 inhibited all isolates, including methicillin-resistant Staphylococcus aureus and Streptococcus faecalis, at a concentration of less than or equal to 2.0 mg/l. The MBCs of this new drug were within eight times the MICs for all bacteria tested.

Anti-Bacterial Agents↗
PubMed1987

In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.

The in vitro activity of S-25930 and S-25932, two new 4-quinolones, against 450 aerobic gram-negative organisms isolated from cancer patients was evaluated and compared with the activity of ciprofloxacin, enoxacin, difloxacin (A-56619), and A-56620. Both agents inhibited most members of the family Enterobacteriaceae at concentrations of less than or equal to 2.0 micrograms/ml, but their activity against Pseudomonas aeruginosa was inferior to that of other quinolones. Although considerably less active than ciprofloxacin and A-56620, S-25930 was frequently two- to eightfold more active than S-25932 and was comparable to difloxacin and enoxacin against most isolates.

Anti-Bacterial Agents↗
PubMed1987

In vitro activity of paldimycin (U-70138F) against gram-positive bacteria isolated from patients with cancer.

The in vitro activity of paldimycin, a novel antimicrobial agent, was compared with that of vancomycin against 306 gram-positive isolates (representing 12 bacterial species) obtained from patients with cancer. Paldimycin had lower MICs for 90% of isolates than vancomycin did against most isolates tested. Its activity, however, was medium and pH dependent, being greatest in Nutrient broth at a pH of 6.8.

Acetylcysteine↗
PubMed1987

In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.

The in vitro activity of two new quinolones, difloxacin and A-56620, was compared with that of other quinolones against isolates obtained from bacteremic cancer patients. Both agents had a broad antimicrobial spectrum which included both gram-positive and gram-negative organisms. A-56620 had lower MIC values against most organisms tested than difloxacin, and its activity was comparable to that of ciprofloxacin.

Anti-Bacterial Agents↗
PubMed1986

In-vitro activity of RU 28965, a new macrolide, compared to that of erythromycin.

The activity of a novel macrolide, RU 28965, was compared to that of erythromycin against Gram-positive organisms isolated mainly from cancer patients. RU 28965 was active against streptococci including Streptococcus pneumoniae and streptococcal groups A, B and G. It was also active against methicillin-susceptible staphylococci, Bacillus cereus and Listeria monocytogenes. Its activity against these organisms was generally equal to that of erythromycin. RU 28965 was moderately active against enterococci and inactive against JK diphtheroids and three different species of coagulase-negative staphylococci. Organisms resistant to erythromycin were also resistant to RU 28965.

Anti-Bacterial Agents↗
PubMed1986

Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients.

Cefpirome and six other antimicrobial agents were tested against 884 blood culture isolates from cancer patients. Cefpirome was highly active against aerobic gram-negative bacilli including Acinetobacter spp., and the Enterobacteriaceae. Only imipenem was more active than cefpirome against Pseudomonas aeruginosa. Cefpirome was also extremely active against beta-hemolytic streptococci and methicillin-susceptible staphylococci.

Anti-Bacterial Agents↗
PubMed1985

Clinical pharmacology of timentin (ticarcillin and clavulanic acid).

Ticarcillin (4 gm) and clavulanic acid (0.1 gm) were simultaneously administered as timentin to patients with cancer as therapy for infections. The pharmacokinetics of both ticarcillin and clavulanic acid were studied in 15 patients after 30-minute and 2-hour intravenous infusions. The mean (+/- SD) ticarcillin plasma peak concentrations after the two infusions were 341 +/- 76 and 210 +/- 60 micrograms/ml. The plasma terminal t1/2 values of ticarcillin were 80 +/- 32 and 56 +/- 12 minutes. The AUCs were 631 +/- 189 and 601 +/- 230 mg/L X hr. The volumes of distribution of the area were 15 +/- 5 and 21 +/- 7 L and total clearances were 115 +/- 36 and 127 +/- 54 ml/min. The corresponding values for clavulanic acid after the infusions are as follows: mean peak concentrations, 5 +/- 1 and 4 +/- 1 micrograms/ml; plasma terminal t1/2 values, 84 +/- 24 and 74 +/- 36 minutes; AUCs, 11 +/- 3 and 11 +/- 6 mg/L X hr; volumes of distribution of the area, 22 +/- 3 and 32 +/- 6 L; and total clearances, 170 +/- 58 and 175 +/- 68 ml/min.

Adult↗
PubMed1985

In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

BMY-28142 was compared with other broad-spectrum antibiotics against gram-positive cocci and gram-negative bacilli. BMY-28142 was highly active against all gram-negative bacilli and especially against Enterobacter cloacae, Serratia marcescens, and Morganella morganii. Its in vitro activity suggests that BMY-28142 should prove to be useful for the treatment of gram-negative bacillary infections.

Anti-Bacterial Agents↗
PubMed1984

In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients.

The activity of WIN 49375 [6-fluoro-1, 4-dihydro-1-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid], a new synthetic quinolone, was tested in vitro against 587 clinical isolates. The MICs for 90% of isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were 0.20, 1.56, and 0.39 microgram/ml, respectively. The MICs for 90% of isolates of Pseudomonas aeruginosa and Serratia marcescens were both 3.12 micrograms/ml. WIN 49375 was minimally active against gram-positive cocci. Its in vitro activity suggests that it may be useful for the treatment of gram-negative bacillary infections.

Anti-Bacterial Agents↗